Di­a­betes-fo­cused Pox­el names Eli Lil­ly vet David Moller as CSO; Ac­celeron's CBO hops ship to lead start­up

→ Af­ter pass­ing their third straight Phase III tri­al for its new kind of di­a­betes tablet in Japan, French phar­ma Pox­el has tapped David Moller as CSO. Moller has fo­cused his ca­reer in the fields of di­a­betes and meta­bol­ic dis­or­ders. He most re­cent­ly served as CSO at Sig­ilon Ther­a­peu­tics and has pre­vi­ous­ly com­plet­ed stints at Eli Lil­ly, as VP of en­docrine and car­dio­vas­cu­lar re­search and clin­i­cal in­ves­ti­ga­tion, and Mer­ck, as VP of meta­bol­ic dis­or­ders. With his new role, Moller will be based in Boston.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER